Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe

Alice Gottlieb; Jordi Gratacos; Ara Dikranian; Astrid van Tubergen; Lara Fallon; Birol Emir; Laraine Aikman; Timothy Smith; Linda Chen

doi:10.1007/s00296-018-4195-x

Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe

Alice Gottlieb^*, Jordi Gratacos, Ara Dikranian, Astrid van Tubergen, Lara Fallon, Birol Emir, Laraine Aikman, Timothy Smith, Linda Chen

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Psoriatic arthritis (PsA) is a chronic, inflammatory disease. The effects of PsA real-world treatment patterns on patient-reported outcomes in the US and 5 European countries (EU5; France, Germany, Italy, Spain, UK) were evaluated. Respondents from the 2016 National Health and Wellness Survey received advanced therapies (e.g., biologic disease-modifying antirheumatic drugs [DMARDs]), other therapies, (e.g., conventional synthetic DMARDs), or no treatment. Assessments included demographics, disease severity (patient-reported), comorbidities (Charlson Comorbidity Index), health status (Short Form-36 Health Survey), depression (Patient Health Questionnaire-9), work productivity (Work Productivity and Activity Index), and treatment adherence (Morisky Medication Adherence Scale-8). Overall, 1037 respondents from the US and 947 respondents from the EU5 were included. Of these, 21.7% US and 7.3% EU5 respondents received advanced therapies; 16.6% and 28.5%, other therapies; and 61.7% and 64.2%, no treatment, respectively. During treatment with advanced or other therapies, 40.8-54.7% US and 57.7-58.9% EU5 respondents self-reported moderate or severe PsA. Respondents receiving advanced therapies had the highest Charlson Comorbidity Index score (US, 1.25; EU5, 1.42); the lowest scores were with no treatment (0.52 and 0.49, respectively). Employment was lowest with other therapies (US, 47.7%; EU5, 41.1%). Overall work impairment was reported by 57.9% US and 62.6% EU5 respondents receiving advanced therapies. Medication adherence was generally low in the US and medium in the EU5 (Morisky Medication Adherence Scale-8: low, US 40.1-46.7%, EU5, 29.0-35.2%; medium, US 29.3-36.1%, EU5 37.8-49.3%; high, US 23.8-24.0%; EU5, 21.7-27.0%). Advanced and other therapies reduced PsA severity; however, >40% of respondents reported moderate or severe PsA during treatment. Better management and adherence may reduce unmet need and disease burden. Further work is required to improve PsA diagnosis and time to treatment initiation.

Original language	English
Pages (from-to)	121-130
Number of pages	10
Journal	Rheumatology International
Volume	39
Issue number	1
DOIs	https://doi.org/10.1007/s00296-018-4195-x
Publication status	Published - Jan 2019

Keywords

Arthritis
psoriatic
Health status
Patient-reported outcome measures
Surveys and questionnaires
Therapeutics
QUALITY-OF-LIFE
RHEUMATOID-ARTHRITIS
MULTINATIONAL ASSESSMENT
MYOCARDIAL-INFARCTION
CLINICAL-FEATURES
RISK-FACTORS
PREVALENCE
BURDEN
DISEASE
MANAGEMENT

Access to Document

10.1007/s00296-018-4195-xLicence: CC BY

Cite this

@article{a6f05c5963fa45b6a77ec0ca79f5a915,

title = "Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe",

abstract = "Psoriatic arthritis (PsA) is a chronic, inflammatory disease. The effects of PsA real-world treatment patterns on patient-reported outcomes in the US and 5 European countries (EU5; France, Germany, Italy, Spain, UK) were evaluated. Respondents from the 2016 National Health and Wellness Survey received advanced therapies (e.g., biologic disease-modifying antirheumatic drugs [DMARDs]), other therapies, (e.g., conventional synthetic DMARDs), or no treatment. Assessments included demographics, disease severity (patient-reported), comorbidities (Charlson Comorbidity Index), health status (Short Form-36 Health Survey), depression (Patient Health Questionnaire-9), work productivity (Work Productivity and Activity Index), and treatment adherence (Morisky Medication Adherence Scale-8). Overall, 1037 respondents from the US and 947 respondents from the EU5 were included. Of these, 21.7% US and 7.3% EU5 respondents received advanced therapies; 16.6% and 28.5%, other therapies; and 61.7% and 64.2%, no treatment, respectively. During treatment with advanced or other therapies, 40.8-54.7% US and 57.7-58.9% EU5 respondents self-reported moderate or severe PsA. Respondents receiving advanced therapies had the highest Charlson Comorbidity Index score (US, 1.25; EU5, 1.42); the lowest scores were with no treatment (0.52 and 0.49, respectively). Employment was lowest with other therapies (US, 47.7%; EU5, 41.1%). Overall work impairment was reported by 57.9% US and 62.6% EU5 respondents receiving advanced therapies. Medication adherence was generally low in the US and medium in the EU5 (Morisky Medication Adherence Scale-8: low, US 40.1-46.7%, EU5, 29.0-35.2%; medium, US 29.3-36.1%, EU5 37.8-49.3%; high, US 23.8-24.0%; EU5, 21.7-27.0%). Advanced and other therapies reduced PsA severity; however, >40% of respondents reported moderate or severe PsA during treatment. Better management and adherence may reduce unmet need and disease burden. Further work is required to improve PsA diagnosis and time to treatment initiation.",

keywords = "Arthritis, psoriatic, Health status, Patient-reported outcome measures, Surveys and questionnaires, Therapeutics, QUALITY-OF-LIFE, RHEUMATOID-ARTHRITIS, MULTINATIONAL ASSESSMENT, MYOCARDIAL-INFARCTION, CLINICAL-FEATURES, RISK-FACTORS, PREVALENCE, BURDEN, DISEASE, MANAGEMENT",

author = "Alice Gottlieb and Jordi Gratacos and Ara Dikranian and {van Tubergen}, Astrid and Lara Fallon and Birol Emir and Laraine Aikman and Timothy Smith and Linda Chen",

note = "Funding Information: Beiersdorf Inc., Bristol-Myers Squibb, Celgene Corp, Dermira, Incyte, Janssen, Lilly, Novartis, Reddy Labs, Sun Pharmaceutical Industries, UCB, Valeant, and XBiotech, and has received research/educational grants from Incyte, Janssen, Lilly, Novartis and UCB. J Gratacos has received consulting fees or other remuneration from AbbVie, Celgene, Janssen-Cilag, MSD, Novartis, Pfizer Inc, and UCB. A Dikranian has received consulting fees or other remuneration from, and has held nonremunerative positions of influence with, AbbVie and Pfizer Inc, is a member of an advisory board for Novartis and Pfizer Inc, and is a member of the speakers{\textquoteright} bureaus for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Mallinckrodt, Novartis, and Pfizer Inc. A van Tuber-gen has received grants, research, or clinical trial support from Ab-bVie, Celgene, Janssen-Cilag, MSD, Novartis, Pfizer Inc, and UCB, is a member of the speakers{\textquoteright} bureaus for Janssen-Cilag, MSD, and Pfizer Inc, and is a consultant or member of an advisory board for Janssen-Cilag, Novartis, and Pfizer Inc. L Fallon, B Emir, L Aikman, and T Smith are shareholders and employees of Pfizer Inc. L Aikman is a shareholder of Pfizer Inc and former employee of Pfizer UK. L Chen is a shareholder and former employee of Pfizer Inc. Funding Information: The authors thank the respondents to the 2016 National Health and Wellness Survey. Medical writing support under the guidance of the authors was provided by Richard Knight, PhD, at CMC Connect, a division of Complete Medical Communications Ltd, Macclesfield, UK, and Carole Evans, PhD, on behalf of CMC Connect, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461?464). Funding Information: This study was funded by Pfizer Inc. Funding Information: Acknowledgements The authors thank the respondents to the 2016 National Health and Wellness Survey. Medical writing support under the guidance of the authors was provided by Richard Knight, PhD, at CMC Connect, a division of Complete Medical Communications Ltd, Macclesfield, UK, and Carole Evans, PhD, on behalf of CMC Connect, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461–464). Publisher Copyright: {\textcopyright} 2018, The Author(s).",

year = "2019",

month = jan,

doi = "10.1007/s00296-018-4195-x",

language = "English",

volume = "39",

pages = "121--130",

journal = "Rheumatology International",

issn = "0172-8172",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe

AU - Gottlieb, Alice

AU - Gratacos, Jordi

AU - Dikranian, Ara

AU - van Tubergen, Astrid

AU - Fallon, Lara

AU - Emir, Birol

AU - Aikman, Laraine

AU - Smith, Timothy

AU - Chen, Linda

N1 - Funding Information: Beiersdorf Inc., Bristol-Myers Squibb, Celgene Corp, Dermira, Incyte, Janssen, Lilly, Novartis, Reddy Labs, Sun Pharmaceutical Industries, UCB, Valeant, and XBiotech, and has received research/educational grants from Incyte, Janssen, Lilly, Novartis and UCB. J Gratacos has received consulting fees or other remuneration from AbbVie, Celgene, Janssen-Cilag, MSD, Novartis, Pfizer Inc, and UCB. A Dikranian has received consulting fees or other remuneration from, and has held nonremunerative positions of influence with, AbbVie and Pfizer Inc, is a member of an advisory board for Novartis and Pfizer Inc, and is a member of the speakers’ bureaus for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Mallinckrodt, Novartis, and Pfizer Inc. A van Tuber-gen has received grants, research, or clinical trial support from Ab-bVie, Celgene, Janssen-Cilag, MSD, Novartis, Pfizer Inc, and UCB, is a member of the speakers’ bureaus for Janssen-Cilag, MSD, and Pfizer Inc, and is a consultant or member of an advisory board for Janssen-Cilag, Novartis, and Pfizer Inc. L Fallon, B Emir, L Aikman, and T Smith are shareholders and employees of Pfizer Inc. L Aikman is a shareholder of Pfizer Inc and former employee of Pfizer UK. L Chen is a shareholder and former employee of Pfizer Inc. Funding Information: The authors thank the respondents to the 2016 National Health and Wellness Survey. Medical writing support under the guidance of the authors was provided by Richard Knight, PhD, at CMC Connect, a division of Complete Medical Communications Ltd, Macclesfield, UK, and Carole Evans, PhD, on behalf of CMC Connect, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461?464). Funding Information: This study was funded by Pfizer Inc. Funding Information: Acknowledgements The authors thank the respondents to the 2016 National Health and Wellness Survey. Medical writing support under the guidance of the authors was provided by Richard Knight, PhD, at CMC Connect, a division of Complete Medical Communications Ltd, Macclesfield, UK, and Carole Evans, PhD, on behalf of CMC Connect, and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461–464). Publisher Copyright: © 2018, The Author(s).

PY - 2019/1

Y1 - 2019/1

N2 - Psoriatic arthritis (PsA) is a chronic, inflammatory disease. The effects of PsA real-world treatment patterns on patient-reported outcomes in the US and 5 European countries (EU5; France, Germany, Italy, Spain, UK) were evaluated. Respondents from the 2016 National Health and Wellness Survey received advanced therapies (e.g., biologic disease-modifying antirheumatic drugs [DMARDs]), other therapies, (e.g., conventional synthetic DMARDs), or no treatment. Assessments included demographics, disease severity (patient-reported), comorbidities (Charlson Comorbidity Index), health status (Short Form-36 Health Survey), depression (Patient Health Questionnaire-9), work productivity (Work Productivity and Activity Index), and treatment adherence (Morisky Medication Adherence Scale-8). Overall, 1037 respondents from the US and 947 respondents from the EU5 were included. Of these, 21.7% US and 7.3% EU5 respondents received advanced therapies; 16.6% and 28.5%, other therapies; and 61.7% and 64.2%, no treatment, respectively. During treatment with advanced or other therapies, 40.8-54.7% US and 57.7-58.9% EU5 respondents self-reported moderate or severe PsA. Respondents receiving advanced therapies had the highest Charlson Comorbidity Index score (US, 1.25; EU5, 1.42); the lowest scores were with no treatment (0.52 and 0.49, respectively). Employment was lowest with other therapies (US, 47.7%; EU5, 41.1%). Overall work impairment was reported by 57.9% US and 62.6% EU5 respondents receiving advanced therapies. Medication adherence was generally low in the US and medium in the EU5 (Morisky Medication Adherence Scale-8: low, US 40.1-46.7%, EU5, 29.0-35.2%; medium, US 29.3-36.1%, EU5 37.8-49.3%; high, US 23.8-24.0%; EU5, 21.7-27.0%). Advanced and other therapies reduced PsA severity; however, >40% of respondents reported moderate or severe PsA during treatment. Better management and adherence may reduce unmet need and disease burden. Further work is required to improve PsA diagnosis and time to treatment initiation.

AB - Psoriatic arthritis (PsA) is a chronic, inflammatory disease. The effects of PsA real-world treatment patterns on patient-reported outcomes in the US and 5 European countries (EU5; France, Germany, Italy, Spain, UK) were evaluated. Respondents from the 2016 National Health and Wellness Survey received advanced therapies (e.g., biologic disease-modifying antirheumatic drugs [DMARDs]), other therapies, (e.g., conventional synthetic DMARDs), or no treatment. Assessments included demographics, disease severity (patient-reported), comorbidities (Charlson Comorbidity Index), health status (Short Form-36 Health Survey), depression (Patient Health Questionnaire-9), work productivity (Work Productivity and Activity Index), and treatment adherence (Morisky Medication Adherence Scale-8). Overall, 1037 respondents from the US and 947 respondents from the EU5 were included. Of these, 21.7% US and 7.3% EU5 respondents received advanced therapies; 16.6% and 28.5%, other therapies; and 61.7% and 64.2%, no treatment, respectively. During treatment with advanced or other therapies, 40.8-54.7% US and 57.7-58.9% EU5 respondents self-reported moderate or severe PsA. Respondents receiving advanced therapies had the highest Charlson Comorbidity Index score (US, 1.25; EU5, 1.42); the lowest scores were with no treatment (0.52 and 0.49, respectively). Employment was lowest with other therapies (US, 47.7%; EU5, 41.1%). Overall work impairment was reported by 57.9% US and 62.6% EU5 respondents receiving advanced therapies. Medication adherence was generally low in the US and medium in the EU5 (Morisky Medication Adherence Scale-8: low, US 40.1-46.7%, EU5, 29.0-35.2%; medium, US 29.3-36.1%, EU5 37.8-49.3%; high, US 23.8-24.0%; EU5, 21.7-27.0%). Advanced and other therapies reduced PsA severity; however, >40% of respondents reported moderate or severe PsA during treatment. Better management and adherence may reduce unmet need and disease burden. Further work is required to improve PsA diagnosis and time to treatment initiation.

KW - Arthritis

KW - psoriatic

KW - Health status

KW - Patient-reported outcome measures

KW - Surveys and questionnaires

KW - Therapeutics

KW - QUALITY-OF-LIFE

KW - RHEUMATOID-ARTHRITIS

KW - MULTINATIONAL ASSESSMENT

KW - MYOCARDIAL-INFARCTION

KW - CLINICAL-FEATURES

KW - RISK-FACTORS

KW - PREVALENCE

KW - BURDEN

KW - DISEASE

KW - MANAGEMENT

U2 - 10.1007/s00296-018-4195-x

DO - 10.1007/s00296-018-4195-x

M3 - Article

C2 - 30426237

SN - 0172-8172

VL - 39

SP - 121

EP - 130

JO - Rheumatology International

JF - Rheumatology International

IS - 1

ER -

Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe

Abstract

Keywords

Access to Document

Fingerprint

Cite this